The Value of Promoter Methylation of Fibroblast Factor 21 (FGF21) in Predicting the Course of Chronic Hepatitis B and the Occurrence of Oxidative Stress

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2024 Dec 22

PMID 39710689

Authors

Xue Li

Pei Liu

Zhaohui Wang

Xuefei Wei

Shuai Gao

Yuchen Fan

Huihui Liu

Kai Wang

Affiliations

Soon will be listed here.

Abstract

Background: Oxidative stress plays a crucial role in the pathogenesis of HBV. This study aimed to investigate the value of fibroblast growth factor 21 (FGF21) promoter methylation in the occurrence and development of chronic hepatitis B (CHB) oxidative stress.

Methods: A total of 241 participants including 221 patients with CHB and 20 healthy controls (HCs) were recruited. Methylation level of FGF21 promoter in peripheral blood mononuclear cells was quantitatively determined. Enzyme-linked immunosorbent assay was used to assess oxidative stress in CHB patients.

Results: Our study shows that the FGF21 methylation level was significantly lower in HBeAg-positive CHB patients compared to HBeAg-negative CHB patients and HCs (P < 0.0001). The oxidative stress of HBeAg-positive CHB patients was more severe. Further correlation analysis showed that there was a significant correlation between the methylation level of FGF21 promoter and the occurrence of oxidative stress in CHB patients. In addition, assessment based on FGF21 promoter methylation level proved effective for predicting oxidative stress occurrence and disease progression among CHB patients.

Conclusion: FGF21 promoter methylation level is an important marker for predicting oxidative stress and disease progression in patients with CHB.

References

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Rusli F, Deelen J, Andriyani E, Boekschoten M, Lute C, van den Akker E . Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep. 2016; 6:30484. PMC: 4965761. DOI: 10.1038/srep30484. View

Raptis D, Mantzoros C, Polyzos S . Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Ther Clin Risk Manag. 2023; 19:77-96. PMC: 9879042. DOI: 10.2147/TCRM.S352008. View

Liu Z, Luo Y, Fang A, Wusiman M, He T, Liu X . High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: A prospective cohort study. Liver Int. 2021; 42(3):663-673. DOI: 10.1111/liv.15100. View

Luangmonkong T, Suriguga S, Mutsaers H, Groothuis G, Olinga P, Boersema M . Targeting Oxidative Stress for the Treatment of Liver Fibrosis. Rev Physiol Biochem Pharmacol. 2018; 175:71-102. DOI: 10.1007/112_2018_10. View

Campbell E, Colgan S . Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2018; 16(2):106-120. PMC: 7919748. DOI: 10.1038/s41575-018-0079-5. View

Popa G, Popa M . Oxidative Stress in Chronic Hepatitis B-An Update. Microorganisms. 2022; 10(7). PMC: 9318593. DOI: 10.3390/microorganisms10071265. View

Pollicino T, Caminiti G . HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses. 2021; 13(3). PMC: 7996909. DOI: 10.3390/v13030368. View

Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C . Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Sci Rep. 2016; 6:31026. PMC: 4976373. DOI: 10.1038/srep31026. View

10.

Tabari F, Karimian A, Parsian H, Rameshknia V, Mahmoodpour A, Majidinia M . The roles of FGF21 in atherosclerosis pathogenesis. Rev Endocr Metab Disord. 2019; 20(1):103-114. DOI: 10.1007/s11154-019-09488-x. View

11.

Khetsuriani N, Lesi O, Desai S, Armstrong P, Tohme R . Progress Toward the Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Worldwide, 2016-2021. MMWR Morb Mortal Wkly Rep. 2022; 71(30):958-963. PMC: 9345178. DOI: 10.15585/mmwr.mm7130a2. View

12.

Sadasivam N, Kim Y, Radhakrishnan K, Kim D . Oxidative Stress, Genomic Integrity, and Liver Diseases. Molecules. 2022; 27(10). PMC: 9147071. DOI: 10.3390/molecules27103159. View

13.

Lu F, Wang J, Chen X, Xu D, Xia N . Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med. 2017; 11(4):502-508. DOI: 10.1007/s11684-017-0590-z. View

14.

Seen S . Chronic liver disease and oxidative stress - a narrative review. Expert Rev Gastroenterol Hepatol. 2021; 15(9):1021-1035. DOI: 10.1080/17474124.2021.1949289. View

15.

Mansouri A, Gattolliat C, Asselah T . Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology. 2018; 155(3):629-647. DOI: 10.1053/j.gastro.2018.06.083. View

16.

Zhang J, Gupte J, Gong Y, Weiszmann J, Zhang Y, Lee K . Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action. EBioMedicine. 2017; 15:173-183. PMC: 5233823. DOI: 10.1016/j.ebiom.2016.12.016. View

17.

Chien R, Liaw Y . Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses. 2022; 14(2). PMC: 8877417. DOI: 10.3390/v14020434. View

18.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

19.

Zhu M, Wang H, Lou T, Xiong P, Zhang J, Li L . Current treatment of chronic hepatitis B: Clinical aspects and future directions. Front Microbiol. 2022; 13:975584. PMC: 9493448. DOI: 10.3389/fmicb.2022.975584. View

20.

Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View